Tibet Aim Pharm Inc
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcoh… Read more
Tibet Aim Pharm Inc (002826) - Total Liabilities
Latest total liabilities as of September 2025: CN¥256.63 Million CNY
Based on the latest financial reports, Tibet Aim Pharm Inc (002826) has total liabilities worth CN¥256.63 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tibet Aim Pharm Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Tibet Aim Pharm Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tibet Aim Pharm Inc Competitors by Total Liabilities
The table below lists competitors of Tibet Aim Pharm Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nuvoco Vistas Corporation Limited
NSE:NUVOCO
|
India | ₹108.95 Billion |
|
Cheng Loong Corp
TW:1904
|
Taiwan | NT$40.99 Billion |
|
Hunan Sokan New Materials Co. Ltd. A
SHG:688157
|
China | CN¥400.49 Million |
|
Shenzhen Fuanna Bedding and Furnishing Co Ltd
SHE:002327
|
China | CN¥1.09 Billion |
|
Real Brokerage Inc
NASDAQ:REAX
|
USA | $91.62 Million |
|
Guizhou Transp Planning
SHG:603458
|
China | CN¥2.70 Billion |
|
2G Energy AG
XETRA:2GB
|
Germany | €120.19 Million |
|
Hotai Finance Corp
TW:6592
|
Taiwan | NT$281.09 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Tibet Aim Pharm Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tibet Aim Pharm Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tibet Aim Pharm Inc (2013–2024)
The table below shows the annual total liabilities of Tibet Aim Pharm Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥180.89 Million | +1.81% |
| 2023-12-31 | CN¥177.68 Million | -33.75% |
| 2022-12-31 | CN¥268.21 Million | +157.00% |
| 2021-12-31 | CN¥104.36 Million | -52.76% |
| 2020-12-31 | CN¥220.94 Million | +20.58% |
| 2019-12-31 | CN¥183.24 Million | +31.32% |
| 2018-12-31 | CN¥139.53 Million | +8.36% |
| 2017-12-31 | CN¥128.76 Million | +41.61% |
| 2016-12-31 | CN¥90.93 Million | -39.16% |
| 2015-12-31 | CN¥149.44 Million | +67.36% |
| 2014-12-31 | CN¥89.30 Million | +9.66% |
| 2013-12-31 | CN¥81.43 Million | -- |